Widespread ongoing research in the role of epigenetics in diseases and disorders in humans is fuelling the global epigenetics drugs and diagnostic technologies market, finds a report published by Transparency Market Research. The report, titled, “Epigenetics Drugs and Diagnostic Technologies Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 – 2018,” states that the market stood at a valuation of US$1.6 bn in 2011. At a CAGR of 19.4% between 2012 and 2018, the market is expected to rise to US$5.7 bn by 2018.
A rise in the number of aged people worldwide is helping the global epigenetics drugs and diagnostic technologies market grow rapidly. This, in turn, is attributable to the strong correlation between aging and various types of diseases. Between 2000 and 2050, the global geriatric population (60 years and above) is expected to double, the WHO reckons. The organization expects that 22% of the global population would comprise people aged 60 years or more. This age group carries a higher risk of diseases such as cancer.
Owing to the increasing economic burden of diseases such as cancer and diabetes, governments across the world are advocating the adoption of early disease detection and diagnosis. Early cancer detection, especially, is being encouraged through screening kids such as Epi ProLung and Epi Procolon. This is aiding the growth of the global epigenetics drugs and diagnostic technologies market, states the report.
Epigenetic drugs are considered effective because they can help reverse aberrant gene expression, which could lead to various diseases. Histone Deacetylase (HDAC) and DNA methyltransferase (DNMT) are the inhibitors that regulate cellular expression. Of these, DNA methyltransferases hold a larger share in the market as they offer improved pathways to target cancerous cells.
The FDA-approved drugs that are currently available commercially include DNMT inhibitors, Vidaza (azacitidine) by Celgene and Dacogen (decitabine) from Eisai. These drugs have been approved for treating Myelodysplastic Syndrome (MDS). The epigenetics drugs market also features Zolinza (vorinostat) by Merck and Istodax (romidepsin) from Celegne, which are both HDAC inhibitors and have been approved for treating Cutaneous T Cell Lymphoma (CTCL).
However, epigenetics is stretching beyond oncology and is proving effective in several non-oncology indications, including arthritis and Alzheimers. This will give companies in the global epigenetics drugs and diagnostic technologies market a larger playing field.
Download Brochure: website growth is expanding rapidly. Asia accounts for about half all cancer cases diagnosed worldwide. This creates conducive conditions for the growth of the epigenetic drugs and diagnostics market in Asian countries, especially China, Japan, Australia, pokercc and South Korea, with Japan in the dominant position.
Some of the most dominant companies in the global epigenetics drugs and diagnostic technologies market are: Merck, Celgene Corporation, Exact Sciences, Eisai Pharmaceuticals, and Epigenomics.
The global epigenetics drugs and diagnostic technologies market is segmented into the following categories:
Epigenetics Drugs Market, by Mechanism of Action
Epigenetics Diagnostic Technologies Market, by Types
Chromatin Immunoprecipitation (ChIP) Technology
Epigenetics Technologies Market, by Geography
Mr. Sudip S
Transparency Market Research
90 State Street,
NY – 12207
USA – Canada Toll Free 866-552-3453
Website: website Epigenetics Drugs and Diagnostic Technologies Market to Account for US$5.7 bn by 2018